{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:48:56Z","timestamp":1790174936964,"version":"4.1.0"},"reference-count":85,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2989,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2007.01361.x","type":"journal-article","created":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T11:37:22Z","timestamp":1182857842000},"page":"20-27","source":"Crossref","is-referenced-by-count":33,"special_numbering":"supplement s153","title":["Pioglitazone and sulfonylureas: effectively treating type 2 diabetes"],"prefix":"10.1155","volume":"61","author":[{"given":"M.","family":"Hanefeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,26]]},"reference":[{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clinthera.2006.03.005","article-title":"Prevalence of inadequate glycaemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002","volume":"28","author":"Fox","year":"2006","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). The UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB3|cit3","first-page":"4047","article-title":"Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes","volume":"86","author":"Kahn","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB4|cit4","first-page":"444","volume-title":"Diabetic Med","volume":"5","author":"UKPDS Study Group","year":"1988"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1462-8902.2004.00357.x","article-title":"Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes","volume":"6","author":"Bell","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/diacare.29.03.06.dc05-0695","article-title":"Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-na\u00efve patients","volume":"29","author":"Rosenstock","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","article-title":"Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women","volume":"51","author":"Buchanan","year":"2002","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","article-title":"Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes","volume":"55","author":"Xiang","year":"2006","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4158\/EP.12.S1.20","article-title":"An update on the diabetes prevention program","volume":"12","author":"Ratner","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB11|cit11","first-page":"287","article-title":"Type 2 diabetes mellitus as a conformational disease","volume":"6","author":"Hayden","year":"2005","journal-title":"JOP"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2337\/diacare.27.9.2253","article-title":"Lipids and glucose in type 2 diabetes: what is the cause and effect","volume":"27","author":"Boden","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB13|cit13","first-page":"683","article-title":"Management of type 2 diabetes mellitus. Role of thiazolidinediones","volume":"51","author":"Nobel","year":"2005","journal-title":"Can Fam Physician"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0889-8529(05)70221-8","article-title":"Oral therapies for diabetic hyperglycemia","volume":"30","author":"Lebovitz","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB15|cit15","first-page":"1747","article-title":"Oral agents in the management of type 2 diabetes mellitus","volume":"63","author":"Luna","year":"2001","journal-title":"Am Fam Physician"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: efficacy of addition of insulin over 6\u2003years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/dmrr.253","article-title":"Are all glitazones the same","volume":"18","author":"Van Gaal","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2337\/diacare.28.3.544","article-title":"Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2\u2003years in patients with type 2 diabetes","volume":"28","author":"Tan","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.amjmed.2003.07.023","article-title":"Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomised trial","volume":"116","author":"Aljabri","year":"2004","journal-title":"Am J Med"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00125-005-1751-1","article-title":"Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes","volume":"48","author":"Charbonnel","year":"2005","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB22|cit22","first-page":"A478","article-title":"Combination therapy with pioglitazone and either metformin or sulfonylurea: glycemic results from PROactive [abstract]","volume":"55","author":"Charbonnel","year":"2006","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB23|cit23","first-page":"A473","article-title":"Efficacy and safety of pioglitazone in addition to SU or Met vs FC with Met plus glyburide in T2 diabetes Pts [abstract]","volume":"55","author":"Comaschi","year":"2006","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB24|cit24","first-page":"490","article-title":"Evaluation of changes of glycaemic control and lipid parameters in patients with T2DM after one year of treatment with pioglitazone in combination with metformin or sulfonylurea in a Greek observational study [abstract]","volume":"49","author":"Ginis","year":"2006","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.27.1.141","article-title":"One-year glycemic control with a sulfonylurea plus pioglitazone vs. a sulfonylurea plus metformin in patients with type 2 diabetes","volume":"27","author":"Hanefeld","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB26|cit26","first-page":"A481","article-title":"Conversion of type 2 diabetic patients treated with a conventional insulin regimen to oral treatment with pioglitazone and glimepiride improves insulin resistance and does not result in an overall deterioration of metabolic control [abstract]","volume":"55","author":"Hohberg","year":"2006","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0002-9343(01)00713-6","article-title":"Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study","volume":"111","author":"Kipnes","year":"2001","journal-title":"Am J Med"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.diabres.2004.10.007","article-title":"A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome","volume":"69","author":"Derosa","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.metabol.2006.02.003","article-title":"The place of sulfonylureas in the therapy for type 2 diabetes mellitus","volume":"55","author":"Del Prato","year":"2006","journal-title":"Metabolism"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.niox.2005.09.002","article-title":"Nitric oxide involvement in pancreatic beta cell apoptosis by glibenclamide","volume":"14","author":"Ansar","year":"2006","journal-title":"Nitric Oxide"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB31|cit31","first-page":"7900","article-title":"Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely: evidence supporting specific desensitization rather than beta-cell exhaustion","volume":"74","author":"Davilli","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1124\/jpet.105.097501","article-title":"Glibenclamide-induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1 (M1289T)","volume":"316","author":"Hambrock","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1006\/bbrc.2000.2616","article-title":"Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells","volume":"271","author":"Iwakura","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1210\/jc.2004-0699","article-title":"Sulfonylurea induced beta-cell apoptosis in cultured human islets","volume":"90","author":"Maedler","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-291X(03)00310-3","article-title":"Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide","volume":"303","author":"Kimoto","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1152\/ajpendo.00331.2003","article-title":"Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes","volume":"286","author":"Diani","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2337\/diabetes.50.5.1021","article-title":"\u03b2-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death","volume":"50","author":"Finegood","year":"2001","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1073\/pnas.96.20.11513","article-title":"Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats","volume":"96","author":"Higa","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.metabol.2003.11.021","article-title":"Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db\/db mice: possible protection of beta cells from oxidative stress","volume":"53","author":"Ishida","year":"2004","journal-title":"Metabolism"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"E510","DOI":"10.1152\/ajpendo.00128.2004","article-title":"Structural and functional analysis of pancreatic islets preserved by pioglitazone in db\/db mice","volume":"288","author":"Kawasaki","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1463-1326.2000.00099.x","article-title":"Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat","volume":"2","author":"Smith","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1152\/ajpendo.00149.2002","article-title":"Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db\/db mice","volume":"284","author":"Yajima","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1016\/j.amjmed.2003.08.010","article-title":"B-cell rejuvenation with thiazolidinediones","volume":"115","author":"Bell","year":"2003","journal-title":"Am J Med"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1126\/science.1104345","article-title":"Type 2 diabetes - a matter of beta cell life and death","volume":"307","author":"Rhodes","year":"2005","journal-title":"Science"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2337\/diabetes.52.10.2461","article-title":"A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes","volume":"52","author":"Kashyap","year":"2003","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB46|cit46","first-page":"1584","article-title":"Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans","volume":"80","author":"Zhou","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1462-8902.2004.00325.x","article-title":"The effects of oral anti-hyperglycaemic medication on serum lipid profiles in patients with type 2 diabetes","volume":"6","author":"Buse","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1210\/jc.2004-0446","article-title":"Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta","volume":"89","author":"Zeender","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/diabetes.53.6.1509","article-title":"Diabetes due to a progressive defect in \u03b2-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat). A new model for type 2 diabetes","volume":"53","author":"Butler","year":"2004","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2337\/diabetes.54.7.2235","article-title":"Long-term treatment with rosiglitazone and metformin reduces the extent of, but does no prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide","volume":"54","author":"Hull","year":"2005","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1210\/jc.2005-0079","article-title":"Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet amyloid polypeptide toxicity by a phosphatidylinositol 3\u2032-kinase-dependent pathway","volume":"90","author":"Lin","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jacc.2006.08.054","article-title":"Anti-inflammatory effects of pioglitazone and\/or simvastatin in high cardiovascular-risk patients with elevated high sensitivity-CRP: the PIOSTAT study","volume":"49","author":"Hanefeld","year":"2007","journal-title":"JACC"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00019501-200108000-00011","article-title":"The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus","volume":"12","author":"Rosenblatt","year":"2001","journal-title":"Coron Artery Dis"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1464-5491.2004.01218.x","article-title":"An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study","volume":"21","author":"Wallace","year":"2004","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1210\/jc.2004-0705","article-title":"Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2337\/diabetes.49.5.782","article-title":"Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes","volume":"49","author":"Buchanan","year":"2000","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1172\/JCI119562","article-title":"Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance","volume":"100","author":"Cavaghan","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2337\/diacare.27.11.2585","article-title":"Effect of rosiglitazone vs. insulin on the pancreatic \u03b2-cell function of subjects with type 2 diabetes","volume":"27","author":"Ovalle","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB59|cit59","first-page":"A150","article-title":"Long-term (2-year) effects on HOMA-%S, an estimate of insulin sensitivity, of pioglitazone, gliclazide and metformin as add-on therapies in patients with T2DM [abstract]","volume":"53","author":"Urquhart","year":"2004","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-2007-979835","article-title":"The effect of glimerpiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus","volume":"28","author":"Clark","year":"1996","journal-title":"Horm Metab Res"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-8227(98)00056-4","article-title":"Pioglitazone enhances splanchic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus","volume":"41","author":"Kawamori","year":"1998","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2337\/diacare.24.4.710","article-title":"Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone","volume":"24","author":"Miyazaki","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1185\/030079904125003386","article-title":"Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes","volume":"20","author":"Tan","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1620\/tjem.183.173","article-title":"Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM","volume":"183","author":"Yamasaki","year":"1997","journal-title":"Tohoku J Exp Med"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1464-5491.2006.01801.x","article-title":"Comparison of glycaemic control over 1\u2003year with pioglitazone or gliclazide in patients with type 2 diabetes","volume":"23","author":"Periello","year":"2006","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2337\/diacare.28.2.266","article-title":"Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes","volume":"28","author":"Ceriello","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.2337\/diabetes.53.suppl_3.S156","article-title":"The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium","volume":"53","author":"Quast","year":"2004","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1503\/cmaj.050748","article-title":"Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study","volume":"174","author":"Simpson","year":"2006","journal-title":"CMAJ"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00045391-200603000-00009","article-title":"Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs","volume":"13","author":"Johnsen","year":"2006","journal-title":"Am J Ther"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2005.01.055","article-title":"Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway","volume":"183","author":"Ueba","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0735-1097(98)00557-9","article-title":"Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction","volume":"33","author":"Garratt","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2337\/diabetes.51.3.808","article-title":"Effect of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes","volume":"51","author":"Scognamiglio","year":"2002","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3132\/dvdr.2004.006","article-title":"Pioglitazone plus a sulfonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes","volume":"1","author":"Perez","year":"2004","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB75|cit75","first-page":"704","article-title":"Lipid and apolipoprotein levels improve with pioglitazone plus sulfonylurea after treatment conversion from rosiglitazone in subjects with type 2 diabetes and dyslipidemia who continue stable statin therapy [abstract]","volume":"49","author":"Khan","year":"2006","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1185\/030079903125002937","article-title":"Impact of adjunctive thiazolidinedione therapy on blood levels and glycemic control in patients with type 2 diabetes","volume":"20","author":"Peters Harmel","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00125-005-0034-1","article-title":"Long-term effects on lipids and lipoproteins of pioglitazone vs. gliclazide addition to metformin and pioglitazone vs. metformin addition to sulfonylurea in the treatment of type 2 diabetes","volume":"48","author":"Betteridge","year":"2005","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB78|cit78","first-page":"69","article-title":"The effects of long-term pioglitazone therapy on lipid profiles in high-risk type 2 diabetes patients: results from PROactive [abstract]","volume":"49","author":"Spanheimer","year":"2006","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB79|cit79","first-page":"493","article-title":"The efficacy and safety of pioglitazone in addition to SU or metformin vs fixed combination of metformin plus glibenclamide on diabetic dyslipidaemia [abstract]","volume":"49","author":"Torre","year":"2006","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1291\/hypres.28.917","article-title":"Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride","volume":"28","author":"Derosa","year":"2005","journal-title":"Hypertens Res"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/01.CIR.0000025403.20953.23","article-title":"Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus","volume":"106","author":"Haffner","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.0000069272.06194.91","article-title":"Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease","volume":"107","author":"Marx","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1210\/jc.2003-032103","article-title":"Evidence for a potent anti-inflammatory effect of rosiglitazone","volume":"89","author":"Mohanty","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2005.03.041","article-title":"Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study","volume":"45","author":"Pfutzner","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2007.01361.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0149-2918(04)90074-4","article-title":"Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial","volume":"26","author":"Derosa","year":"2004","journal-title":"Clin Ther"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2007.01361.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2007.01361.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:07:27Z","timestamp":1643350047000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2007.01361.x"}},"subtitle":["Treating type 2 diabetes with pioglitazone and sulfonylureas"],"short-title":[],"issued":{"date-parts":[[2007,6,26]]},"references-count":85,"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01361.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6,26]]}}}